1e
19
1
49
2
2
18
1b
1d
18
32
59
1d
2 29
1d
25
David H. Henry, M.D.
88
59
Clinical Professor of Medicine (Hematology-Oncology)
28
94
3
5f
Director, AIDS Malignancy Program, University of Pennsylvania Cancer Center, Philadelphia, PA
85
Vice Chairman, Department of Medicine, Pennsylvania Hospital, Philadelphia, PA
92
Associate Program Director, Department of Medicine, Pennsylvania Hospital, Philadelphia, PA
77
Education Officer, Department of Medicine, Pennsylvania Hospital
65
Penn Medicine Clinician, Pennsylvania Hospital
11
Department: Medicine
4
1
b
1d
46
Contact information
46
4
3
3
3
2
4
b
1f
46
Penn Hematology/Oncology
1e Abramson Cancer Center
34 Pennsylvania Hospital, Farm Journal Building
3d 230 West Washington Square
Philadelphia, PA 19106
26
1e Abramson Cancer Center
34 Pennsylvania Hospital, Farm Journal Building
3d 230 West Washington Square
Philadelphia, PA 19106
2e
Office: 215-829-6088
32 Fax: 215-829-6104
24
95
32 Fax: 215-829-6104
24
Email:
david.henry@uphs.upenn.edu
12
david.henry@uphs.upenn.edu
13
Education:
21 9 B.A. c
2d Princeton University, 1970.
21 9 M.D. c
46 University of Pennsylvania School of Medicine, 1975.
c
3
3
3
3
8a
Permanent link21 9 B.A. c
2d Princeton University, 1970.
21 9 M.D. c
46 University of Pennsylvania School of Medicine, 1975.
c
2 29
21
1e
1d
24
2b
29
27
23
259 Reid E, Suneja G, Alexiev B, Ard K, Baiocchi R, Campbell T, Carchman E, Cohen S, Dickson MA, Eschenauer G, Goyal G, Grilley-Olson J, Gupta A, Henry DH, Hicks D, Jones A, Klopp A, Korpics M, LaCasce AS, Lee T, Lin C, Maurer T, Menon MP, Morgan D, Nathwani N, Palm D, Park HS, Ratner L, Rizza S, Sanchez J, Schorge J, Timmerman J, Vogt S, Wang CJ, Freedman-Cass D, Sansone N, Schonfeld R.: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cancer in People with HIV. National Comprehensive Cancer Network 2025.
182 Evani Patel, Parisa Wootton, Clare Connolly, Patricia A. Locantore-Ford, Fumei Cerecino, Rebecca Pesce-Noga, David H. Henry: Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can be Safely Conducted at Lower Hemoglobin Thresholds. Blood 144 (Supplement 1), November 2024.
124 Emily Tomasulo, Sailaja Vinnakota, Michael Auerbach, David H. Henry, Patricia A. Locantore-Ford: Optimization of Iron Deficiency Screening, Diagnosis, and Treatment in Pregnancy. Blood 144 (Supplement 1), November 2024.
199 Evani Patel, Parisa Wootton, Clare Connolly, Patricia A. Locantore-Ford, Fumei Cerecino, Rebecca Pesce-Noga, David H. Henry: Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can Be Safely Conducted At Lower Hemoglobin Thresholds. International Journal of Cancer Care and Delivery October 2024.
189 Mittelman M, Henry DH, Glaspy JA, Tombak A, Harrup R, Kim I, Mądry K, Grabowska B, Lee T, Modelska K.: Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. Am J Hematol. 99(9): 1778-1789, June 2024 Notes: DOI: 10.1002/ajh.27410.
a9 David Henry: ASCO 2024: Abstract Recommendations From Dr. David Henry. PracticeUpdates May 2024.
17d Gina Nicholson 1, Katherine B Carlson 2, Rohini K Hernandez 2, Jennifer Schenfeld 2, Benoit Cadieux 3, David Henry 4, Vitor Jose De Sousa Barbosa 3, Hossam Saad 3: Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients with Bone Metastases. American Journal of Clinical Oncology January 2024.
cc David Henry: A commentary on: Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. Practiceupdate 2024.
132 David Henry: A commentary on: Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. PracticeUpdate 2024.
2c
7
1d
1f
Selected Publications
258 Reid E, Suneja G, Alexiev B, Ard K, Baiocchi R, Campbell T, Carchman E, Cohen S, Dickson MA, Eschenauer G, Goyal G, Grilley-Olson J, Gupta A, Henry DH, Hicks D, Jones A, Klopp A, Korpics M, LaCasce AS, Lee T, Lin C, Maurer T, Menon MP, Morgan D, Nathwani N, Palm D, Park HS, Ratner L, Rizza S, Sanchez J, Schorge J, Timmerman J, Vogt S, Wang CJ, Freedman-Cass D, Nguyen J, Sansone N, Schonfeld R.: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Kaposi Sarcoma. National Comprehensive Cancer Network 2025.259 Reid E, Suneja G, Alexiev B, Ard K, Baiocchi R, Campbell T, Carchman E, Cohen S, Dickson MA, Eschenauer G, Goyal G, Grilley-Olson J, Gupta A, Henry DH, Hicks D, Jones A, Klopp A, Korpics M, LaCasce AS, Lee T, Lin C, Maurer T, Menon MP, Morgan D, Nathwani N, Palm D, Park HS, Ratner L, Rizza S, Sanchez J, Schorge J, Timmerman J, Vogt S, Wang CJ, Freedman-Cass D, Sansone N, Schonfeld R.: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cancer in People with HIV. National Comprehensive Cancer Network 2025.
182 Evani Patel, Parisa Wootton, Clare Connolly, Patricia A. Locantore-Ford, Fumei Cerecino, Rebecca Pesce-Noga, David H. Henry: Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can be Safely Conducted at Lower Hemoglobin Thresholds. Blood 144 (Supplement 1), November 2024.
124 Emily Tomasulo, Sailaja Vinnakota, Michael Auerbach, David H. Henry, Patricia A. Locantore-Ford: Optimization of Iron Deficiency Screening, Diagnosis, and Treatment in Pregnancy. Blood 144 (Supplement 1), November 2024.
199 Evani Patel, Parisa Wootton, Clare Connolly, Patricia A. Locantore-Ford, Fumei Cerecino, Rebecca Pesce-Noga, David H. Henry: Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can Be Safely Conducted At Lower Hemoglobin Thresholds. International Journal of Cancer Care and Delivery October 2024.
189 Mittelman M, Henry DH, Glaspy JA, Tombak A, Harrup R, Kim I, Mądry K, Grabowska B, Lee T, Modelska K.: Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. Am J Hematol. 99(9): 1778-1789, June 2024 Notes: DOI: 10.1002/ajh.27410.
a9 David Henry: ASCO 2024: Abstract Recommendations From Dr. David Henry. PracticeUpdates May 2024.
17d Gina Nicholson 1, Katherine B Carlson 2, Rohini K Hernandez 2, Jennifer Schenfeld 2, Benoit Cadieux 3, David Henry 4, Vitor Jose De Sousa Barbosa 3, Hossam Saad 3: Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients with Bone Metastases. American Journal of Clinical Oncology January 2024.
cc David Henry: A commentary on: Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. Practiceupdate 2024.
132 David Henry: A commentary on: Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. PracticeUpdate 2024.
2c